Initial Treatment Recommendation for Rheumatoid Arthritis

Pathogenesis and Treatment Approach

• The European League Against Rheumatism recommends starting methotrexate as the first-line treatment for patients with newly diagnosed rheumatoid arthritis, unless contraindicated 1, 2, 3

Initial Treatment Algorithm

• The American College of Rheumatology suggests that methotrexate should be started as soon as rheumatoid arthritis is diagnosed, with careful monitoring of potential toxicity 1, 2
• Short-term low-dose glucocorticoids (≤10 mg/day prednisone equivalent) can be used as bridging therapy until methotrexate takes effect, as recommended by the European League Against Rheumatism 3, 4

Alternative First-Line Options

• Leflunomide or sulfasalazine can be used as the first treatment strategy in patients with contraindications to methotrexate, according to the European League Against Rheumatism 1, 2, 5
• Leflunomide has similar clinical efficacy to methotrexate in established and early rheumatoid arthritis, with comparable effects on radiographic progression, as reported by the American College of Rheumatology 5

Treatment Strategy and Monitoring

• The European League Against Rheumatism recommends a treat-to-target approach, aiming for remission or low disease activity in every patient, with frequent monitoring of disease activity (every 1-3 months) during active disease 1, 2
• If no improvement is seen by 3 months or the target is not reached by 6 months, therapy should be adjusted, as suggested by the American College of Rheumatology 1, 2

Treatment Escalation

• If methotrexate monotherapy fails and poor prognostic factors are absent, consider adding or switching to another conventional synthetic DMARD, according to the European League Against Rheumatism 1, 2
• If poor prognostic factors are present, consider adding a biological DMARD or JAK inhibitor, as recommended by the American College of Rheumatology 1, 2

Combination Therapy Options

• The most common combination consists of methotrexate, sulfasalazine, and hydroxychloroquine, which has shown efficacy in early rheumatoid arthritis, particularly when used with a treat-to-target approach, as reported by the European League Against Rheumatism 1, 5
• Biological DMARDs should be used in combination with methotrexate when possible, due to superior efficacy of this combination over biologic monotherapy, according to the American College of Rheumatology 3
• TNF inhibitors, IL-6 inhibitors, and other biologics have shown efficacy when added to methotrexate in patients with inadequate response to methotrexate alone, as reported by the European League Against Rheumatism 6, 7

Important Considerations and Pitfalls

• Delayed treatment escalation can be a common pitfall, and therapy should be adjusted if targets are not met within the recommended timeframe, as suggested by the American College of Rheumatology 1, 2